BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 18462565)

  • 1. Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors.
    Hirsch L
    Curr Med Res Opin; 2008 Jun; 24(6):1683-9. PubMed ID: 18462565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
    Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
    BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study.
    DeVito NJ; Bacon S; Goldacre B
    Lancet; 2020 Feb; 395(10221):361-369. PubMed ID: 31958402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with results reporting at ClinicalTrials.gov.
    Anderson ML; Chiswell K; Peterson ED; Tasneem A; Topping J; Califf RM
    N Engl J Med; 2015 Mar; 372(11):1031-9. PubMed ID: 25760355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research without results: inadequate public reporting of clinical trial results.
    Gopal RK; Yamashita TE; Prochazka AV
    Contemp Clin Trials; 2012 May; 33(3):486-91. PubMed ID: 22342449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov.
    Law MR; Kawasumi Y; Morgan SG
    Health Aff (Millwood); 2011 Dec; 30(12):2338-45. PubMed ID: 22147862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial registries and clinical trial result posting: new paradigm for medical writers.
    Foote M
    Biotechnol Annu Rev; 2006; 12():379-86. PubMed ID: 17045200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Registration of clinical trials: a statement from the International Committee of Medical Journal Editors].
    DeAngelis C; Drazen JM; Frizelle FA; Haug C; Hoey J; Horton R; Kotzin S; Laine C; Marusic A; Overbeke AJ; Schroeder TV; Sox HC; van der Weyden MB;
    Ned Tijdschr Geneeskd; 2004 Sep; 148(38):1870-1. PubMed ID: 15497781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance on Mandatory Data Reporting in Registered Obstetrics Trials.
    Checketts JX; Evans MB; Athale AH; Jawhar OM; Wright MR; Bryant K; Vassar M
    Am J Perinatol; 2018 Oct; 35(12):1192-1196. PubMed ID: 29695018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
    Alder HC
    Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating adherence to the International Committee of Medical Journal Editors' policy of mandatory, timely clinical trial registration.
    Huser V; Cimino JJ
    J Am Med Inform Assoc; 2013 Jun; 20(e1):e169-74. PubMed ID: 23396544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial regulation in Argentina: overview and analysis of regulatory framework, use of existing tools, and researchers' perspectives to identify potential barriers.
    White L; Ortiz Z; Cuervo LG; Reveiz L
    Rev Panam Salud Publica; 2011 Nov; 30(5):445-52. PubMed ID: 22262271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugmakers prefer silence on test data; firms violate US law by not registering trials.
    Vedantam S
    Washington Post; 2004 Jul; ():A1, A4. PubMed ID: 15290815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.